Author

C. Rice

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Assay:ATAC-seq· 1 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

A. Cho· 2 shared A. Gazumyan· 2 shared C. Gaebler· 2 shared D. F. Robbiani· 2 shared E. Michailidis· 2 shared F. Muecksch· 2 shared F. Schmidt· 2 shared H.-H. Hoffmann· 2 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Cho

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Th1 cells alter the inflammatory signature of IL-6 by channeling STAT transcription factors to Alu-like retroelements

D. Millrine, A. Cardus Figueras, J. Uceda Fernandez, R. Andrews, B. Szomolay, B. C. Cossins, C. Rice, J. Li, V. Tyrrell, L. mcLeod, P. Holmans, V. O'Donnell, P. Taylor, S. J. Turner, B. J. Jenkins, , S. A. Jones

The paper investigates how IFN-gamma-secreting CD4+ T-cells alter the transcriptional output of IL-6 by redirecting STAT1 and STAT3 to Alu-like retroelements during inflammation.

bioRxiv · Jul 18, 2022 · PreprintImmunology

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Y. Weisblum, F. Schmidt, F. Zhang, J. DaSilva, D. Poston, J. C. C. Lorenzi, F. Muecksch, M. Rutkowska, H.-H. Hoffmann, E. Michailidis, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, , P. D. Bieniasz

The paper shows SARS-CoV-2 variants resistant to neutralizing antibodies can be selected and are present in circulating populations, suggesting the need for combination antibody therapies.

bioRxiv · Jul 21, 2020Microbiology

Discovery of repurposing drug candidates for the treatment of diseases caused by pathogenic free-living amoebae

C. Rice, B. L. Colon, E. Chen, M. V. Hull, D. Kyle

This study identifies 58 potent drug candidates for treating diseases caused by pathogenic free-living amoebae through high-throughput screening of a compound library.

bioRxiv · May 13, 2020Microbiology

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

D. F. Robbiani, C. Gaebler, F. Muecksch, J. Cetrulo Lorenzi, Z. Wang, A. Cho, M. Agudelo, C. Barnes, S. Finkin, T. Hagglof, T. Oliveira, C. Viant, A. Hurley, K. Millard, R. Kost, , Nuss

The paper analyzes antibody responses in convalescent individuals, finding low neutralizing titers but rare potent RBD-specific antibodies with broad antiviral potential.

bioRxiv · May 13, 2020Immunology